Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

Arcutis looks promising, driven by strong Zoryve sales, a solid balance sheet, and a strategic CFO transition. See why I rate ARQT stock a Buy.

Alphabet is a massive cash flow machine with an under-leveraged balance sheet. With EBITDA margins of 35-40% ... coupled with slowing GCP has stoked concerns among some investors. Upcoming remedy ...

Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April ...

Just a few years ago, a high-stakes court case involving Apple and Google would have found the companies on opposing sides, ...

Citizens JMP downgraded Ironwood (IRWD) to Market Perform from Outperform without a price target The stock in midday trading is down 31% to ...

Alphabet is a massive cash flow machine with an under-leveraged balance sheet. With EBITDA margins ... Upcoming remedy trial could prove pivotal. After ruling in mid-2024 that Alphabet maintained ...

ORMP intends to launch a Phase 3 oral insulin trial in the U.S. under a differentiated ... ORMP is also leveraging its balance sheet – about $142 million in cash, equivalents, short-term ...

What To Know: The company acquired 80,567 SOL, bringing its total Solana holdings to 163,651.7 tokens, valued at ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The judge agreed to toss out two of the claims against DCG, its CEO Barry Silbert and Michael Moro, the former CEO of Genesis ...